Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Food effect on pharmacokinetics of HS-10518
NCT06554548Phase 1Not yet recruiting
- Sponsor
- Hansoh Pharmaceutical Group
- Start
- Aug 2024
- Primary completion
- Jul 2025
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, open-label trial of merigolix in endometriosis (2 arms), sponsored by Hansoh Pharmaceutical Group. Primary endpoints: Peak Plasma Concentration at 48 hours and Area Under the Curve from time 0 to time t at 48 hours. Planned start Aug 2024; status: not yet recruiting.
02
Drugs
merigolix
03
Conditions
endometriosis
Beyond the preview
Go deeper on NCT06554548.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06554548.